<a href="https://laohu8.com/S/RSLS">ReShape Lifesciences</a> Inc. Announces $200,000 Loan Agreement with Vyome <a href="https://laohu8.com/S/LENZ">Therapeutics</a> to Support Upcoming Merger
ReShape Lifesciences Inc. has entered into a promissory note agreement with Vyome Therapeutics, Inc., as disclosed in a recent Form 8-K filing. Under this agreement, ReShape will provide a loan of $200,000 to Vyome, intended for working capital and expenses related to their merger agreement dated July 8, 2024. The loan will bear an interest rate of 8% per annum and is due for repayment by September 30, 2025, unless the merger is completed beforehand. If the merger proceeds as planned, Vyome will not have to repay the loan, with the outstanding amount counted as ReShape's net cash under the merger terms. If the merger agreement is terminated under specific conditions, the promissory note will become a senior secured obligation for Vyome.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. ReShape Lifesciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001104659-25-065782), on July 03, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。